Figure 7. FPR agonist Cmpd17b reduces cardiac remodelling 7-day post I–R injury.

(a) Representative CardioTAC-stained LV sections 7-day post I–R; magnification × 200. (b) Quantification of dead:viable cells (expressed as fold sham). (c) Representative picrosirius red-stained LV cross-sections from sham, vehicle- and FPR agonist (Cmpd17b or Cmpd43, both 50 mg kg⁻¹ per day i.p.)-treated mice, 7-day post I–R. (d) Quantification of cardiac fibrosis (collagen appears red); magnification × 200. (e) Heart and (f) LV weight normalized to BW 7-day post I–R. Results are expressed as mean±s.e.m. ^##P<0.01, ^####P<0.0001 versus sham; *P<0.01, ***P<0.001, ****P<0.0001 versus vehicle-treated mice on one-way ANOVA with Dunnett's post hoc test (n, number of mice per group, indicated below the x axis). Shams (open symbols); I–R (black symbols); Cmpd17b (blue symbols); Cmpd43 (red symbols).